Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of ...

Corcept's relacorilant hits phase 3 trial success in ovarian cancer, lifting shares 90%. Click here to find out why I rate ...

Corcept Therapeutics' stock surged over 80% after its Phase 3 ROSELLA trial met its primary goal. See why we still consider ...

Corcept (CORT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...

A new drug tested in a phase 3 trial showed significant improvement in patients with treatment-resistant ovarian cancer.

Equities researchers at Zacks Research lifted their Q1 2026 earnings per share (EPS) estimates for shares of Corcept ...

Menlo Park-based Corcept Therapeutics said on Monday its experimental drug in combination with chemotherapy helped delay ...

Corcept Therapeutics (NASDAQ:CORT – Free Report) had its target price lifted by Piper Sandler from $128.00 to $131.00 in a report issued on Thursday,Benzinga reports. The brokerage currently has an ...

Investors with a lot of money to spend have taken a bearish stance on Corcept Therapeutics CORT. And retail traders should ...

Mid-cap stocks surged in the past week, including CORT, COOP, and CRWV. GOOG may rent AI servers from CRWV. PRGS and LOAR ...

Corcept Therapeutics Incorporated’s CORT share price has dipped by 9.93%, which has investors questioning if this is right time to buy.

Learn more about whether Corcept Therapeutics Incorporated or Sanofi is a better investment based on AAII's A+ Investor ...